We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$489M
AUM Growth
+$31.8M
Cap. Flow
+$66.3M
Cap. Flow %
13.55%
Top 10 Hldgs %
49.33%
Holding
85
New
24
Increased
27
Reduced
16
Closed
16

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$12.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$9.19M
4
SLNO
Soleno Therapeutics
SLNO
+$8.1M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$7.71M

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$17.3M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$15M
3
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$9.72M
4
SRRK icon
Scholar Rock
SRRK
+$7.92M
5
COGT icon
Cogent Biosciences
COGT
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
76
Olema Pharmaceuticals
OLMA
$1B
– –
-233,281
Closed -$1.36M
PCVX icon
77
Vaxcyte
PCVX
$7.81B
– –
-40,788
Closed -$3.34M
PLRX icon
78
Pliant Therapeutics
PLRX
$64.4M
– –
-1,315,601
Closed -$17.3M
RARE icon
79
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-124,388
Closed -$5.23M
SNDX icon
80
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-172,400
Closed -$2.28M
SRRK icon
81
Scholar Rock
SRRK
$5.67B
– –
-183,243
Closed -$7.92M
VRDN icon
82
Viridian Therapeutics
VRDN
$2.09B
– –
-100,000
Closed -$1.92M
BIOA
83
BioAge Labs
BIOA
$402M
– –
-39,974
Closed -$231K
ITCI
84
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-179,085
Closed -$15M
PSTX
85
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-1,012,307
Closed -$9.72M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Silverarc Capital Management held 85 positions worth $489M, up 7% from $457M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Silverarc Capital Management deployed $66.3M of net new capital in Q1 2025, opening 24 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 72,583 shares worth $8.03M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Centessa Pharmaceuticals, an estimated $5.99M trimmed.

  • Silverarc Capital Management's largest Q1 2025 buy was Neurocrine Biosciences: 72,583 shares worth $8.03M.
  • Silverarc Capital Management added most to 89bio in Q1 2025, an estimated $12.4M increase.
  • Silverarc Capital Management's biggest Q1 2025 reduction was Centessa Pharmaceuticals, cutting an estimated $5.99M.
  • Silverarc Capital Management fully exited Pliant Therapeutics in Q1 2025, selling an estimated $17.3M.
  • Silverarc Capital Management's ten largest holdings make up 49% of its $489M portfolio in Q1 2025.
  • Silverarc Capital Management opened 24 new positions and closed 16 in Q1 2025.
  • Silverarc Capital Management's portfolio value rose 7% quarter-over-quarter to $489M.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.